Cargando…
Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib
The fusion of echinoderm microtubule-associated protein-like 4 with the anaplastic lymphoma kinase (EML4-ALK) is found in 3%–7% of non-small-cell lung cancer (NSCLC) cases and confers sensitivity to crizotinib, the first United States Food and Drug Administration (FDA)-approved ALK inhibitor drug. A...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4638315/ https://www.ncbi.nlm.nih.gov/pubmed/26622190 http://dx.doi.org/10.2147/PGPM.S71100 |